Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business
AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid pandemic.
Britain’s biggest drugmaker has agreed to take over the Seattle-based company Icosavax, which is developing a potential vaccine for two common respiratory diseases.
More Stories
Toxic wildfire pollution infiltrates homes of 1bn people a year, study finds
AI can spontaneously develop human-like communication, study finds
The Cybertruck was supposed to be apocalypse-proof. Can it even survive a trip to the grocery store?